EMN UKMPPD GALIH

download EMN UKMPPD GALIH

of 32

Transcript of EMN UKMPPD GALIH

  • 8/16/2019 EMN UKMPPD GALIH

    1/32

    UKMPPD BATCH II

    2015 LULUS 100%

  • 8/16/2019 EMN UKMPPD GALIH

    2/32

    SISTEM ENDOKRINE, METABOLIKDAN NUTRISI

    • DM tipe 1 4A

    • DM tipe 2 4A

    Hipogi!e"i# $ig#4A• M#&t$i'i ee$gi p$otei4A

    • De('ie'i )it#"i 4A

    De('ie'i Mie$#4A• Hipe$&$i'e"i# 4A

    • O*e'it#'4A

  • 8/16/2019 EMN UKMPPD GALIH

    3/32

    DM

    • Di#*ete' Meit&' #+## g#gg"et#*oi! -#g +it#+#i oeipe$gi!e"i# #!i*#t +e.e! p#+# !e$/#i'&i $e'i'te'i i'&i +# 'e!$e'ii'&i #t#& !e++-#3

  • 8/16/2019 EMN UKMPPD GALIH

    4/32

    • Hasil Anamnesis (Subjective)

    • Ke&#

    • 13 Poi.#gi#

    • 23 Poi&$i• 3 Poi+ip'i

    • 43 Pe&$&# *e$#t *#+# -#g ti+#! /e#' 'e*#*-#

    • Ke&# ti+#! !#' DM

    • 13 Le"#

    • 23 Ke'e"&t# $#'# *## +i &/&g&/&g e!'t$e"it#'

    • 3 6#t#

    • 43 M#t# !#*&$

    • 53 Di'.&g'i e$e!'i p#+# p$i#

    • 73 P$&$it&' 8&8#e p#+# 9#it#

    • :3 L&!# -#g '&it 'e"*&

  • 8/16/2019 EMN UKMPPD GALIH

    5/32

    • ;#!to$ $i'i!o DM tipe 2

    • 13 Be$#t *#+# e*i +# o*e'e IMT < 25 !g="2

    • 23 Ri9#-#t pe-#!it DM +i !e$g#

    3 Meg##"i ipe$te'i TD < 140=>0 ""Hg #t#&'e+#g +##" te$#pi ipe$te'i

    • 43 Pe$# +i+i#go'i' pe-#!it /#t&g #t#& 't$o!e!#$+io8#'!&#$

    • 53 Koe'te$o HDL ? 5 "g=+ +# = #t#& T$igi'e$i+# @250 "g =+L #t#& 'e+#g +##" pego*#t#+i'ipi+e"i#

    • 73 Ri9#-#t "e#i$!# *#-i +eg# BBL @ 4000 g$#"#t#& pe$# +i+i#go'i' DM 6e't#'io#

    :3 Pe$e"p +eg# $i9#-#t PCOS  polycistic ovarysyndrome

    • 3 Ri9#-#t 6DPT 6&!o'# D#$# P'# te$g#g& = T6TToe$#'i 6&!o'# Te$g#gg&

    • >3 A!ti(t#' /#'"#i -#g !&$#g

  • 8/16/2019 EMN UKMPPD GALIH

    6/32

    • Hasil Pemeriksaan Fisik dan penunjang sederhana(Objective)

    • Pe"e$i!'## ;i'i! P#togo"oi'

    • Pe&$&# *e$#t *#+# -#g ti+#! /e#' pe-e*#*-#

    • ;#!to$ P$e+i'po'i'i

    • 13 U'i# @ 45 t#&

    • 23 Diet tiggi !#o$i +# e"#!

    • 3 A!ti(t#' ('i! -#g !&$#g

    • 43 Hipe$te'i TD < 140=>0 ""Hg

    • 53 Ri9#-#t toe$#'i g&!o'# te$g#gg& T6T #t#& g&!o'# +#$#p'# te$g#gg& 6DPT

    • 73 Pe+e$it# pe-#!it /#t&g !o$oe$, t&*e$!&o'i',ipe$ti$oi+i'"e

    • :3 Di'ipi+e"i#

  • 8/16/2019 EMN UKMPPD GALIH

    7/32

    • Pe"e$i!'## Pe&/#g

    • 13 6&# D#$# P'#

    • 23 6&# D#$# 2 /#" Po't P$#+i#

    • 3 H*A1C

    • Penegakan Diagnosis ( Assessment )

    • Di#go'i' Kii'

    • K$ite$i# +i#go'ti! DM +# g#gg toe$#'i g&!o'#

    • 13 6e/## !#'i! DM poi&$i#, poi+ip'i#, poi.#gi g&!o'# p#'"#'e9#!t& < 200 "g=+L 1131 ""o=L3 6&!o'# p#'"# 'e9#!t&"e$&p#!# #'i pe"e$i!'## 'e'##t p#+# 't& #$i t#p#"e"pe$#ti!# 9#!t& "#!# te$#!i$3 ATAU

    • 23 6e/## K#'i! DM K#+#$ g&!o'# p#'"# p'# < 127 "g=+3 P'#+i#$ti!# p#'ie ti+#! "e+#p#t !#o$i t#"*## 'e+i!it-# /#" ATAU

    • 3 K#+#$ g&!o'# p#'"# 2 /#" p#+# te' toe$#'i g&!o'# te$g#gg&TT6O @ 200 "g=+L 1131 ""o=L TT6O +i#!&!# +eg# 't#+#$+HO, "egg&#!# *e*# g&!o'# #i+$&' :5 g$#" -#g +i#$&t!#+##" #i$3 ATAU

    • 43 H*A1C Peet +i#go'i' DM *e$+#'#$!# H*A1C < 735 % *e&"+#p#t +ig&#!# 'e#$# #'io# +i I+oe'i#, "egig#t 't#+#$i'#'ipe"e$i!'## -#g "#'i *e&" *#i!3

  • 8/16/2019 EMN UKMPPD GALIH

    8/32

    • Ap#*i# #'i pe"e$i!'## ti+#! "e"e&i !$ite$i#o$"# #t#& DM, "#!# +#p#t +igoog!# !e +##"!eo"po! T6T #t#& 6DPT te$g#t&g +#$i #'i

    -#g +ipe$oe• K$ite$i# g#gg toe$#'i g&!o'#

    • 13 6DPT +iteg#!!# *i# 'ete# pe"e$i!'##g&!o'# p#'"# p'# +i+#p#t!# #t#$# 100125

    "g=+ 53773> ""o=• 23 T6T +iteg#!!# *i# 'ete# pe"e$i!'## TT6O

    !#+#$ g&!o'# p#'"# 1401>> "g=+ p#+# 2 /#"'e'&+# *e*# g&!o'# :5 g$#" :3 1131 ""o=L

    3 H*A1C 53: 734%F Peet +i#go'i' DM*e$+#'#$!# H*A1C < 735 % *e&" +#p#t+ig&#!# 'e#$# #'io# +i I+oe'i#, "egig#t't#+#$i'#'i pe"e$i!'## -#g "#'i *e&" *#i!3

  • 8/16/2019 EMN UKMPPD GALIH

    9/32

  • 8/16/2019 EMN UKMPPD GALIH

    10/32

    • K#'i(!#'i DM

    • I3 DM tipe 1

    • DM p#+# &'i# "&+#, ? 40 t#&

    • I'&i dependent #!i*#t +e't$&!'i'e

    • #3 Immune-mediated

    *3 I+iop#ti!

    • II3 DM tipe 2 *e$8#$i#'i "&#i +#$i -#g p$e+o"i# $e'i'te'i i'&i +eg#+e('ie'i i'&i $e#ti. +o"i# +e.e! 'e!$e'i i'&i +i'e$t#i $e'i'te'i i'&i

    • III3 Tipe #i

    • #3 De.e! geeti! p#+# .&g'i 'e G

    • *3 De.e! geeti! p#+# !e$/# i'&i• 3 Pe-#!it e!'o!$i p#!$e#'

    • +3 E+o!$iop#ti

    • e3 A!i*#t o*#t #t#& #t !i"i# te$tet& "i'#-# 8acor, pentamidine, nicotinic acid,g&!o!o$ti!oi+, o$"oe ti$oi+, diazoxide, agonis adrenergik, thiazid, phenytoin,interferon, protease inhibitors, clozapine

    • .3 I.e!'i

    • g3 Bet&! ti+#! #i" +#$i i""&e "e+i#te+ DM

    • 3 Si+$o" geeti! #i, -#g !#+#g *e$!#it# +eg# DM

    • I)3 DM ge't#'io#

    • Di#*ete' Meit&' 6e't#'io# DM6 #+## 't& g#gg toe$#'i !#$*oi+$#tT6T, 6DPT, DM -#g te$/#+i #t#& +i!et#&i pe$t#"# !#i p#+# '##t !e#"i# 'e+#g

    *e$#g'&g3

  • 8/16/2019 EMN UKMPPD GALIH

    11/32

    • S!$iig

    • Pei#i# #+#-# $i'i!o DM6 pe$& +i#!&!# 'e/#! !&/&g#pe$t#"# &t&! pe"e$i!'## !e#"i#-#3

    • ;#!to$ $i'i!o DM6 "eip&ti

    • 13 Ri9#-#t DM6 'e*e&"-# #t#& T6T #t#& 6DPT

    • 23 Ri9#-#t !e$g# +eg# +i#*ete'

    • 3 O*e'it#' *e$#t @120% *e$#t *#+# i+e#

    • 43 Ri9#-#t "e#i$!# *#-i +eg# ##t *#9## #t#&

    +eg# *e$#t *#+# #i$ @ 4000 g$• 53 A*o$t&' *e$&#g

    • 73 Ri9#-#t PCOS Po-i'ti O8#$i S-+$o"e

    • :3 Ri9#-#t p$ee!#"p'i#

    • 3 6&!o'&$i#

    • >3 I.e!'i '#&$# !e"i *e$&#g #t#& !#+i+i#'i'

    • P#+# 9#it# #"i -#g "e"ii!i $i'i!o tiggi DM6 pe$&+i#!&!# te' DM6 p#+# "igg& !e24 2 !e#"i#

  • 8/16/2019 EMN UKMPPD GALIH

    12/32

    • Di#go'i'

    • Bi# +i+#p#t!# 6DS < 200 "g=+ #t#& 6DP < 127 "g=+ -#g 'e'i +eg# *#t#'+i#go'i' &t&! +i#*ete', "#!# pe$& +i#!&!# pe"e$i!'## p#+# 9#!t& #i &t&!!o($"#'i3 P#'ie #"i +eg# T6T +# 6DPT +i!eo# 'e*#g#i DM63

    • Di#go'i' B#+ig

    • Di#*ete' i'ipi+&' p#+# i*& #"i

    • Ko"pi!#'i

    • A3 A!&t

    • 13 Keto#'i+o'i' +i#*eti!

    • 23 Hipe$o'"o#$ o !etoti!

    • 3 Hipogi!e"i#

    • B3 K$oi!

    •13 M#!$o#giop#ti

    • 23 Pe"*&& +#$# /#t&g

    • 3 Pe"*&& +#$# pe$i.e$

    • 43 Pe"*&& +#$# ot#!

    • C3 Mi!$o#giop#ti

    • 13 Pe"*&& +#$# !#pie$ $eti#

    • 23 Pe"*&& +#$# !#pie$ $e#

    • D3 Ne&$op#ti

    • E3 6#*&g#

    • 13 K#$+io"iop#ti

    • 23 Ret# i.e!'i

    • 3 K#!i +i#*eti!

    • 43 Di'.&g'i e$e!'i

  • 8/16/2019 EMN UKMPPD GALIH

    13/32

    • Penatalaksanaan komprehensif (Plan)

    • Pe#t##!'###

    •  Te$#pi &t&! Di#*ete' Meit&' +i#!&!# +eg# "o+i(!#'i g#-# i+&p +#pego*#t# #go$it"# pegeo## DM tipe 2

    • Pe#t##!'### DM6 'e*#i!-# +i#!'##!# 'e#$# te$p#+& oe 'pe'i#i'pe-#!it +##", 'pe'i#i' o*'tet$i gie!oogi', #i +iet, +# 'pe'i#i' ##!3

    •  T&/ pe#t##!'### #+## "e&$&!# #g!# !e'#!it# +# !e"#ti#i*&, !e'#!it# +# !e"#ti# pe$i#t#3 Ii #-# +#p#t +i#p#i #p#*i#!e#+## o$"ogi!e"i# +#p#t +ipe$t##!# 'e#"# !e#"i# '#"p#ipe$'#i#3

    • S#'#$# o$"ogi!e"i# DM6 #+## !#+#$ 6DP >5 "g=+ +# 2 /#"'e'&+# "#!# 120 "g=+3 Ap#*i# '#'#$# g&!o'# +#$# ti+#! te$#p#i

    +eg# peg#t&$# "#!# +# #ti# /#'"#i, #g'&g +i*e$i!# i'&i3• I*& #"i +eg# DM6 pe$& +i#!&!# '!$iig DM p#+# 712 "igg& p#'#

    "e#i$!# +# '!$iig DM #/&t# &t&! "ei#t pe$!e"*#g# !e #$#DM #t#& p$e+i#*ete'3

  • 8/16/2019 EMN UKMPPD GALIH

    14/32

  • 8/16/2019 EMN UKMPPD GALIH

    15/32

  • 8/16/2019 EMN UKMPPD GALIH

    16/32

    • C#$# Pe"*e$i# OHO, te$+i$i +#$i

    • 13 OHO +i"&#i +eg# +o'i' !ei +# +itig!#t!#'e#$# *e$t##p'e'i $e'po' !#+#$ g&!o'# +#$#,+#p#t +i*e$i!#'#"p#i +o'i' opti"#3

    • 23 S&.oi&$e# 15 0 "eit 'e*e&" "#!#3• 3 Rep#gii+, N#tegii+ 'e'##t 'e*e&" "#!#3

    • 43 Met.o$"i 'e*e&"=p#+# '##t='e'&+# "#!#3

    • 53 Peg#"*#t g&!o'i+#'e  Acarbose *e$'#"# "#!#

    'p#pe$t#"#3• 73 Ti#oi+i+io ti+#! *e$g#t&g p#+# /#+9# "#!#3

    • :3 DPPI) ii*ito$ +#p#t +i*e$i!# *e$'#"# "#!# +##t#&'e*e&" "#!#3

  • 8/16/2019 EMN UKMPPD GALIH

    17/32

    • Pe"e$i!'## Pe&/#g L#/&t#*i# +ipe$&!#

    • U$i#i'i' p$otei&$i +#"i!$o#*&"i&$i#, .&+&'!opi,&$e&", !$e#tii, ipi+ p$o(, EK6,.oto to$#!3

  • 8/16/2019 EMN UKMPPD GALIH

    18/32

  • 8/16/2019 EMN UKMPPD GALIH

    19/32

    • Ko'eig J E+&!#'i

    • E+&!#'i "eip&ti pe"##"# tet#g

    • 13 Pe-#!it DM3

    • 23 M#!# +# pe$&-# pege+#i# +# pe"#t# DM3

    3 Pe-&it DM3• 43 Ite$8e'i .#$"#!oogi'3

    • 53 Hipogi!e"i#3

    • 73 M#'## !&'&' -#g +i#+#pi3

    • :3 C#$# "ege"*#g!# 'i'te" pe+&!&g +# "eg#/#$!#

    !ete$#"pi#3• 3 C#$# "e"pe$g&#!# .#'iit#' pe$#9#t# !e'e#t#3

    • >3 Pe"*e$i# o*#t /#g!# p#/#g +eg# !ot$o te$#t&$'eti#p 2 "igg&=1 *&#3

  • 8/16/2019 EMN UKMPPD GALIH

    20/32

    • Pe$e### M#!#

    • St#+#$ -#g +i#/&$!# #+## "#!## +eg# !o"po'i'i

    • 13 K#$*oi+$#t 45 75 %

    • 23 P$otei 15 20 %

    3 Le"#! 20 25 %•  &"# !#+&g# !oe'te$o +i'#$#!# ? 00 "g=#$i3

    Di&'##!# e"#! *e$#'# +#$i '&"*e$ #'#" e"#! ti+#! /e& MU;A Mono Unsaturated Fatty Acid, +# "e"*#t#'iPU;A oly Unsaturated Fatty Acid +# #'#" e"#! /e&3

     &"# !#+&g# 'e$#t 25 g=$, +i&t#"#!# 'e$#t #$&t3•  &"# !#o$i *#'# pe$ #$i

    • 13 L#!i#!i 0 !#=!g BB i+#"#

    • 23 #it# 25 !#=!g BB i+#"#

  • 8/16/2019 EMN UKMPPD GALIH

    21/32

    • Pe-e'i# te$#+#p !#o$i *#'# = #$i

    • 13 St#t&' gii

    • BB ge"&! 20 %

    • BB e*i 10 %

    • BB !&$#g 20 %

    23 U"&$ @ 40 t#& 5 %• 3 St$e' "et#*oi! i.e!'i, ope$#'i,+ 10 '=+ 0 %

    • 43 A!ti(t#'

    • Rig# 10 %

    • Se+#g 20 %

    • Be$#t 0 %

    • 53 H#"i

    • t$i"e'te$ I, II 00 !#• t$i"e'te$ III = #!t#'i 500 !#

    • R&"&' B$o#F

    • Be$#t *#+# i+#"# TB 100 10 %

    • !ria " #$% cm dan &anita " #'% cm, tidak dikurangi #% ( lagi)

    BB !&$#g ? >0 % BB i+#"#• BB o$"# >0 110 % BB i+#"#

    • BB e*i 110 120 % BB i+#"#

    • 6e"&! @ 120 % BB i+#"#

    • L#ti# #'"#i

    • Kegi#t# /#'"#i 'e#$i#$i +# #ti# te$#t&$ 4 !#i 'e"igg& 'e#"# !&$#g e*i0 "eit3 Kegi#t# 'e#$i#$i 'epe$ti *e$/## !#!i !e p#'#$, "egg&#!# t#gg#,

    *e$!e*&, #$&' tet#p +i#!&!#3

  • 8/16/2019 EMN UKMPPD GALIH

    22/32

    • K$ite$i# R&/&!#

    • &t&! pe#g## ti+#! #/&t p#+# !o+i'i*e$i!&t

    13 DM +eg# !o"pi!#'i• 23 DM +eg# !ot$o g&# *&$&!

    • 3 DM +eg# i.e!'i *e$#t

    • 43 DM +eg# !e#"i#

    • 53 DM t-pe 1• Pe"#t# +# ti+#! #/&t

    • 13 E+&!#'i +# "##/e"e &t$i'i

    • Be$#t *#+# +i&!&$ 'eti#p !#i !&/&g#

    • Pei#i# $&ti !#+&g#, !tit#', +#peg#t&$# 9#!t& #'&p# "#!##3 Di'e'i!#+eg# !e*&t&#3

    • T#$get pe&$&# *e$#t *#+# "e&/& *e$#t

    *#+# i+e# +# !ot$o g&# +#$# te$#p#i3

  • 8/16/2019 EMN UKMPPD GALIH

    23/32

    • 23 L#ti# ('i!

    • Pei#i# #!ti8it#' ('i! p#ig 'e+i!it 'eti#p tig# *&#'e!#i

    • Re## #ti# pegg#*&g# +eg# pii#

    #!ti8it#' 'e!#$#g ii +# e8e #!ti8it#' +itig!#t!#'#"p#i *#t#' toe$#'i3 Di#/&$!# 150 "eit = "igg&+&$#'i 045 "eit +eg# ite$8# 5 = "igg&+eg# #!ti8it#' ('i! #e$o*i! ite'it#' 'e+#g 50:0%Maximum *eart +ate3

    • A!ti8it#' ('i! +i'e'i!# +eg# !o"pi!#'i DM $i'i!ote$/#+i ipogi!e"i#, e&$op#ti pe$i.e$, !#$+io8#'!&#$,$etiop#ti, +# e.$op#ti

    • T#$get p#'ie "e#!&!# #!ti8it#' ('i! 'e#$# te$#t&$

  • 8/16/2019 EMN UKMPPD GALIH

    24/32

    • 3 Pe$#9#t# !#!i

    • Seti#p !#i p#'ie *e$!&/&g +i#!&!# pe"e$i!'## 8i' !#!i, 'e'i*iit#'e&$op#ti 'e'o$i! , +# 8#'!&#$i'#'i A!e B$#i# I+e= ABI

    • E+&!#'i i'pe!'i p$i*#+i 'eti#p #$i +# pe$#9#t# peeg## 'e#$# te$#t&$

    R&/&!# &t&! pe$#9#t# !&'&', *i# +ipe$&!#• 43 Moito$ig !e"#/ +# #"*#t# pe#t##!'###

    • Le"*#$ #t#t# = $e!#"# +i!e"*#g!# &t&! "eig!#t!# pei#i#p#'ie +# !o"&i!#'i pet&g#' !e'e#t# 'e#$# te$&'"ee$&' "oito$ /#/ipe$te", pe"e$i!'## ('i!, i#i #*o$#to$i&", #'i peg&!&$# p$i*#+i g&#+#$#, "#'##"#'## -#g #!ti., pego*#t#, +# #i#i

    • St$#tegi "eg#t#'i #"*#t# 1 !ot#! teepo !&/&g# 'e"et#$# 2

    "egig#t!# = "egi!&ti = "e"*t /#+9# &#g /#/i pe$te" #!ti8it#''o'i# = e+&!#'i g$&p 4 !#$t& &#p# 'pe'i# = #$i $#-#

    • Me&i' #t#t# "ege#i ite$#!'i p#'ie +i+i'!&'i!# +eg# pet&g#'!e'e#t# !ii! &t&! "e/#"i !e#/&t# +# !it#' pe$#9#t#

    • D&!&g# !o"&it#' A+#-# +&!&g# !e$g# = o$#g #i -#g petig&t&! "eg#t&$ /#/i pe$te" +# !egi#t# #i3

    Pe&g#'# 't#. +ipe$&!# &t&! "egopti"#!# ite$#!'i +# pe$#9#t#,'e$t# "eg&$#gi #"*#t# p#'ie

    • Pei#i# "##/e"e p$i*#+i 'e#$# te$&'"ee$&' "e-e+i#!# ="e&/&!!# &t&! e+&!#'i DM, +# = #t#& pe+o"# #ti#, +&!&g#p'i!o'o'i#, #t#& '&"*e$ +#-# !o"&it#'3

  • 8/16/2019 EMN UKMPPD GALIH

    25/32

    • 53 Peeg## $etiop#ti = pego*#t#

    • Pe"e$i!'## $eti# "#t# +# = #t#& pe"*t#.oto $eti# +i#!&!# 'ege$# 'ete# +i#go'i' DM+iteg#!!# +# +i&#g p#ig 'e+i!it 1 t#& 'e!#i+# e*i 'e$ig *i# #+# $etiop#ti3

    • Ut&! "e&$&!# $i'i!o = "e"pe$#"*#tp$og$e'i8it#' $etiop#ti "#!# pe$& "egopti"#!#

    !ot$o g&# +#$# +# te!## +#$#• Bi# te$+#p#t $etiop#ti, +i$&/&! !e +o!te$ 'pe'i#i'

    "#t#

  • 8/16/2019 EMN UKMPPD GALIH

    26/32

    • 73 Peeg## !#'&' pe-&it

    • Te' &t&! "ei#t e!'!$e'i #*&"i &$i +# !$e#tii 'e$&" p#+# DM +i#!&!#p#+# '##t pe$t#"# !#i +i#go'i' DM +iteg#!!#, 'e$t# +i&#g peg&!&$#-#'e#$# $&ti p#ig 'e+i!it 1 t#& 'e!#i3

    • Ut&! "e&$&!# $i'i!o = "e"pe$#"*#t p$og$e'i8it#' e.$op#ti "#!# pe$&

    "egopti"#!# !ot$o g&# +#$# +# te!## +#$#• P#'ie DM tipe II +eg# Hipe$te'i +# "i!$o#*&"i&$i#, *#i! ACEI = ARB

    +#p#t "e"pe$#"*#t p$og$e'i !e "#!$o#*&"i&$i#

    • P#'ie DM tipe II +eg# ipe$te'i, "#!$o#*&"i&$i#, +# i'&e'i $e#!$e#tii @ 1,5 *e$i!# ARB &t&! "e"pe$#"*#t p$og$e'i8it#' e.$op#ti3

    • Pe"*#t#'# #'&p# p$otei "e/#+i 031 g=!gBB=#$i p#+# DM +eg# 't#+i&"#9# CKD

    • Moito$ !$e#tii 'e$&" +# pot#'i&" &t&! "ei#t AR; +# ipe$!#e"i# p#+#pegg&## ACEI, ARB, #t#& ti#i+

    • Moito$ e!'!$e'i #*&"i &$i &t&! "ei#t $e'po te$#pi +# p$og$e'i8it#'pe-#!it

    • R&/&! !e +o!te$ 'pe'i#i' *i# !#'&' +eg# pe-&it

  • 8/16/2019 EMN UKMPPD GALIH

    27/32

    • :3 M##/e"e ipe$te'i

    • Peg&!&$# te!## +#$# 'eti#p !#i !&/&g#

    • Bi# TD 'i'toi! < 10 ""Hg = +i#'toi! < 0 ""Hg #$&' +i!o($"#'i&#g +i #$i *e$*e+#, *i# i#i-# < 10=0 +i+i#go'i' ipe$te'i

    T#$get TD #+## ? 10 = 0 ""Hg• TD 'i'toi! 101> #t#& +i#'toi! 0> ""Hg "o+i(!#'i g#-# i+&p

    'e#"# "#!'i"# *&#, *i# t#$get ti+#! te$#p#i, t#"*#!# OAH

    • TD 'i'toi! < 140 = +i#'toi! < >0 Q te$#pi OAH "o+i(!#'i g#-# i+&p

    • OAH -#g +ig&#!# #+## ACEI = ARB, *i'# /&g# +it#"*#!# HCT+eg# 6;R < 50 "="i pe$ 1,: "2 = oop +i&$eti +eg# 6;R ? 50

    "="i pe$ 1,: "2• Te$#pi o*#t "&tipe *i#'#-# +ig&#!# &t&! "e#p#i t#$get TD

    • Moito$ 'e#& .&g'i gi/# +# !#+#$ pot#''i&" +#$#

    • P#+# p#'ie #"i +eg# DM, t#$get TD 10012> = 75:> ""Hg O*#t-#g +ip#!#i "eti+op#, #*et#o, +iti#e", oi+i, p$#o'ie

  • 8/16/2019 EMN UKMPPD GALIH

    28/32

    • S#$## p$#'#$##

    • 13 A#t Pe"e$i!'## 6&# D#$# Se+e$##

    • 23 A#t Peg&!&$ *e$#t +# tiggi *#+# ##!

    'e$t# +e9#'#• 3 S!## At$opo"et$i

    • Prognosis

    • P$ogo'i' &"&"-# #+## +&*i#3 K#$e#

    pe-#!it ii #+## pe-#!it !$oi', &o #+ 8it#"&"&"-# #+## +&*i# #+ *o#", #"& &o#+ .&g'io#" +# '##tio#"-# #+## +&*i##+ "##"3

  • 8/16/2019 EMN UKMPPD GALIH

    29/32

    • Referensi

    • 13 S&+o-o, A33 Seti-o#+i, B3 A9i, I3 Si"#+i*$#t#,M3 Seti#ti, S3E+'3 uku aar ilmu penyakit dalam3E+ 43 )o3 III3 #!#$t# P&'#t Pee$*it# Dep#$te"e

    I"& Pe-#!it D##" ;KUI 20073• 23 Pe$!&"p&# E+o!$ioogi I+oe'i#3

    .onsensus engelolaan dan encegahan /iabetesMelitus 0ipe 1 di Indonesia) 20113

    • 3 Dep#$te"e I"& Ke+o!te$# Ko"&it#' ;KUI+# Pe$'#+i#3 Pe#t##!'### Di#*ete' Meit&'p#+# L#-## P$i"e$, e+32, 2012

  • 8/16/2019 EMN UKMPPD GALIH

    30/32

  • 8/16/2019 EMN UKMPPD GALIH

    31/32

    • DM tipe #i itoe$#'i g&!#'i #!i*#t pe-#!it #t#& o*#tA

    • Hipop#$#ti$oi+ A

    • Hipe$ti$oi+ A

    • 6oite$ Di'e#'e A• Keto#'i+o'i' +i#*eti!&" o!etoti! B

    • Hipe$gi!e"i Hipe$o'"o#$ B

    • Hipogi!e"i# Be$#t B

     Ti$oto!'i!o'i'B• C&'ig' +i'e#'e B

    • K$i'i' A+$e# B

    • Si+$o" Met#*oi! B

  • 8/16/2019 EMN UKMPPD GALIH

    32/32

    •  Ti$oi+iti' 2

    • Hipoti$oi+ 2

    P&*e$t#' p$e!o!' 2• Hipogo#+i'"e 2

    • A+eo"# Ti$oi+ 2

    K#$'io"# Ti$oi+ 2